Vojmir Urlep receives the Minařik Award for his outstanding contributions to the development of the pharmaceutical profession
- Vojmir Urlep, President of the Board of Management of Lek and Novartis in Slovenia, received the Minařik Award for his outstanding contributions to the development of pharmacy practice in Slovenia.
- The Minařik Award is the highest award bestowed by the Slovenian Pharmaceutical Society for outstanding achievements of individuals who have excelled in the field of pharmacy.
- The Award confirms Vojmir Urlep’s longstanding efforts and expertise at Lek, today a valued part of the international Novartis group.
Vojmir Urlep, President of the Board of Management of Lek and Novartis in Slovenia, received at the Slovenian Pharmaceutical Society awards ceremony on Thursday, May 11, the Minařik Award, the highest Society award. The Slovenian Pharmaceutical Society bestows this award to individuals for their outstanding achievements in the development of pharmaceutical science in the Slovenian and international arena and for an important contribution to economic and social development.
The Slovenian Pharmaceutical Society reasoned its decision to bestow this highest award in the pharmaceutical profession to Vojmir Urlep saying: »Vojmir Urlep has, together with his colleagues, strived and succeeded to place Slovenia on the map of countries where development and manufacturing activities for not only generic but also novel innovative drug products and drug substances are carried out. In the period from 2007, when Lek has been headed by Vojmir Urlep, the company has doubled the number of development projects and has become a leading Sandoz development center for technologically demanding projects.« Under Urlep’s leadership, Lek has established itself as one of the most successful parts of the global corporation Novartis, strengthened cooperation with scientific-research institutions and projects such as the Regional BioCamp and opened the door to new knowledge and innovative thinking for the future, they added.
Throughout his career, Vojmir Urlep has been demonstrating that the professional knowledge of Slovenian pharmacists can be recognised at the global level even in the most demanding environment. This is one of the reasons, why Lek is today recognised and valued as one of the most successful companies within the Novartis group. »Throughout my career, I have been constantly striving for a broader integration of the Slovenian pharmaceutical profession and its members regardless of which branch of professional expertise they exercise. I trust the knowledge that Slovenian experts possess and believe together we can achieve a great deal. I believe that through cooperation, perseverance and courage we can accomplish many achievements and conquer even the toughest challenges,« said Vojmir Urlep.
Vojmir Urlep is performing the function of the President of the Board of Management of Lek, a Sandoz company, since August 2007. He is also the President of the Supervisory Board of the Chamber of Commerce and Industry of Slovenia, a member of the Executive Board of The Managers’ Association of Slovenia, a member of the organizing committee for the preparation of the annual congress of pharmacists at the Slovenian Pharmaceutical Society, a member of the Strategic Council for Internationalization and the President of the strategic group of foreign-owned companies at the Chamber of Commerce and Industry of Slovenia. In December 2016, he received a plaque »Pro universitate labacensi« for his important contribution to enhance the reputation of the Ljubljana University in the international arena.
The awards were presented as part of a Symposium accompanying a 42nd assembly of the Slovenian Pharmaceutical Society. At the three-day event, more than 430 participants, mostly from the field of pharmacy, will have the opportunity to take part in more than twenty different lectures, symposia and round tables addressing various pharmaceutical topics of current interest.
Lek, a Sandoz company, is one of the key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a key global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar active ingredients and products; a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and the Commonwealth of Independent States (CIS), and is responsible for marketing and sales of Sandoz products on the Slovenian market. For further information, please visit www.lek.si.
Sandoz is a global leader in generic and biosimilar pharmaceuticals. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2016 sales of USD 10.1 billion. In 2016, our products reached more than 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global (link is external).
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32